Janux Therapeutics (JANX) investor relations material

Executive summary

• Report covers the quarter ended June 30, 2025, for a clinical-stage biopharmaceutical company focused on immunotherapies for cancer and autoimmune diseases, with lead candidates JANX007 and JANX008 in Phase 1 trials and a broad preclinical pipeline.

• R&D Day showcased progress in TRACTr, TRACIr, and ARM pipelines, emphasizing best-in-class potential for autoimmune diseases.

• Enrollment is ongoing for JANX007 (prostate cancer) and JANX008 (multiple solid tumors), with data updates expected in H2 2025.

• No product revenue has been generated; all revenue to date is from a collaboration with Merck, which concluded its research phase in August 2024.

• Net losses continue to increase due to higher R&D and administrative expenses, with a significant cash position maintained through recent equity offerings.

Financial highlights

• Net loss for Q2 2025 was $33.9 million, compared to $6.0 million in Q2 2024; net loss for the six months ended June 30, 2025, was $57.4 million, up from $20.7 million year-over-year.

• Research and development expenses rose to $34.7 million in Q2 2025 (from $14.9 million) and $59.7 million for the six months (from $29.0 million), driven by increased preclinical and clinical activities.

• General and administrative expenses increased to $10.5 million in Q2 2025 (from $7.8 million) and $20.3 million for the six months (from $15.2 million), mainly due to higher stock-based compensation and professional fees.

• Cash, cash equivalents, and short-term investments totaled $996.8 million at June 30, 2025, down from $1.03 billion at year-end 2024.

• Interest income rose to $11.3 million in Q2 2025 (from $7.9 million) and $22.6 million for the six months (from $13.3 million), reflecting higher cash and investment balances.

Outlook and guidance

• Expenses and operating losses are expected to increase substantially as research and development activities expand.

• Existing cash, cash equivalents, and short-term investments of $996.8 million as of June 30, 2025, are expected to fund operations for at least the next 12 months.

• No product revenue is anticipated for several years; future funding will rely on equity, debt, or partnership arrangements.

• Additional clinical data from JANX007 and JANX008 will be presented in the second half of 2025.

• Multiple preclinical candidates are advancing toward clinical trials, including TROP2-TRACTr and CD19-ARM.